Vandetanib and ADAM inhibitors synergistically attenuate the pathological migration of EBV-infected retinal pigment epithelial cells by regulating the VEGF-mediated MAPK pathway.
about
Vandetanib and ADAM inhibitors synergistically attenuate the pathological migration of EBV-infected retinal pigment epithelial cells by regulating the VEGF-mediated MAPK pathway.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 February 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Vandetanib and ADAM inhibitors ...... he VEGF-mediated MAPK pathway.
@en
Vandetanib and ADAM inhibitors ...... he VEGF-mediated MAPK pathway.
@nl
type
label
Vandetanib and ADAM inhibitors ...... he VEGF-mediated MAPK pathway.
@en
Vandetanib and ADAM inhibitors ...... he VEGF-mediated MAPK pathway.
@nl
prefLabel
Vandetanib and ADAM inhibitors ...... he VEGF-mediated MAPK pathway.
@en
Vandetanib and ADAM inhibitors ...... he VEGF-mediated MAPK pathway.
@nl
P2093
P2860
P356
P1476
Vandetanib and ADAM inhibitors ...... he VEGF-mediated MAPK pathway.
@en
P2093
Dae Young Hur
Daejin Kim
Ga Bin Park
Hyun-Suk Ko
Jae Wook Yang
Yeong Seok Kim
P2860
P304
P356
10.3892/ETM.2017.4110
P577
2017-02-08T00:00:00Z